KaloBios Rises From Bankruptcy Ashes With PRV Still Firmly In Its Sights
KaloBios Pharmaceuticals Inc.'s CEO Dr Cameron Durrant has ticked off two major tasks from his to-do list in his bid to turn the company around after it was caught in the firestorm of Martin Shkreli's fall from grace. He talks to Scrip about the company's strategy, his vision of a responsible pricing model, and the possibility that KaloBios' actions might help rehabilitate pharma's image.
You may also be interested in...
US FDA’s recent guidance on the program notes that even tropical disease products approved under 505(b)(2) are eligible for a priority review voucher.
KaloBios Pharmaceuticals Inc. is now free of Martin Shkreli, after the pharma 'bad boy' sold his remaining stock, and wants to get on with its work of focusing on R&D of medicines that benefit patients with rare and neglected diseases. But the firm also has some ideas it thinks could change biotech.
In just a few short weeks, Martin Shkreli's empire has collapsed.